Cat.#: ASSD-103
Description | DAPI is a blue fluorescent DNA stain which is cell permeant at high concentrations. This is a ready made 1mg/mL staining solution. It is recommended to dilute this solution 1:1000 with your desired buffer for a 1µg/mL working concentration. 0.1µg/mL-10µg/mL is the typical working concentration used in most applications. DAPI also available. |
Size | 1 mL, 5 mL, |
Applications | The product is commonly used for cell imaging, cell counting, cell sorting (based on DNA content), apoptosis analysis, and HCA (high content analysis). |
Chemical Name | 4',6-Diamidino-2-phenylindole dihydrochloride |
Molecule Weight | 350.24 |
Molecular formula | C16H15N5.2HCl |
CAS Number | 28718-90-3 |
Purity | >98% |
Form | Pale yellow solution |
Storage | Store at -20° C |
Shipping | Shipped at 4°C |
Important | When using this product for the first time, aliquot the DAPI ready-made solution and store at -20°C to avoid repeated freezing and thawing. Additionally, We strongly recommend storing this solution in the dark and away from light due to the compound's light sensitivity. |
Citation Guidance | If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. |
Cat.# | Name | Size | Price |
---|---|---|---|
ASSD-138 | A3AR covalent antagonist (AC138) | 50 μg | inquiry |
ASSD-144 | Oxazole Yellow Iodide (AC144) | 1 mg | inquiry |
ASSD-220 | Nitrofluorescein, Isomer 2 (AC220) | 1 g | inquiry |
ASSD-152 | Biocytin (AC152) | 10 mg, 50 mg | inquiry |
ASSD-166 | FURA-2 (AC166) | 1 mg | inquiry |
ASSD-142 | Methoxy-X04 (AC142) | 10 mg, 50 mg | inquiry |
ASSD-109 | Picro Sirius Red Solution (AC109) | 250 mL | inquiry |
ASSD-171 | Ionomycin calcium salt (AC171) | 1mg, 5mg | inquiry |
ASSD-127 | Fluorescent H3 antagonist [clobenpropit] (AC127) | 50 μg | inquiry |
ASSD-191 | Fluorescein 6-Isothiocyanate, Isomer 2, 95% (AC191) | 100 mg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.